Susquehanna International Group
RAPT

Susquehanna International Group’s RAPT Therapeutics RAPT Stock Holding History

Susquehanna International Group’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,200
Closed -$278K – 13934
2025
Q4 		$278K Buy
+8,200
New +$255K ﹤0.01% 10125
2024
Q2 		– Sell
-1,613
Closed -$116K – 13019
2024
Q1 		$116K Buy
+1,613
New +$224K ﹤0.01% 11117
2022
Q1 		– Sell
-1,363
Closed -$400K – 13808
2021
Q4 		$400K Sell
1,363
-500
-27% -$134K ﹤0.01% 9781
2021
Q3 		$463K Sell
1,863
-28,787
-94% -$7.61M ﹤0.01% 9590
2021
Q2 		$7.79M Buy
30,650
+23,800
+347% +$4.45M ﹤0.01% 3288
2021
Q1 		$1.22M Buy
6,850
+2,000
+41% +$330K ﹤0.01% 7206
2020
Q4 		$766K Buy
+4,850
New +$1.05M ﹤0.01% 7314

Susquehanna International Group's RAPT Position: Q1 2026 in Review

Susquehanna International Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 424,862 shares — an estimated $14.4M sold.

Susquehanna International Group first reported a position in RAPT in Q1 2021 and held it in 15 quarters. The position peaked at $14.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • Susquehanna International Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 424,862 RAPT Therapeutics shares in Q1 2026, an estimated $14.4M.
  • Susquehanna International Group first reported a position in RAPT Therapeutics in Q1 2021 and held it in 15 quarters.
  • Susquehanna International Group's RAPT Therapeutics position peaked at $14.4M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.